This research provides preclinical data to guide the exploration of drug combination strategies with MDM2 inhibitors, supporting the conduct of future clinical trials and the development of associated biomarkers to improve the outcomes for CLL patients. Here, MDM2 is linked to B-cell chronic lymphocytic leukemia.